246 results on '"Hogan, William J."'
Search Results
2. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
3. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
4. Adjusting diffusing capacity for anemia in patients undergoing allogeneic HCT: a comparison of two methodologies
5. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
6. A Day 14 Endpoint for Acute GVHD Clinical Trials
7. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
8. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
9. Effective treatment of low-risk acute GVHD with itacitinib monotherapy
10. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
11. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
12. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
13. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
14. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
15. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
16. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
17. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
18. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation
19. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
20. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience
21. Risk Factors and Outcomes of Nocardiosis in Hematopoietic Stem Cell Transplantation Recipients
22. Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant
23. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved
24. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant
25. Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions
26. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
27. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms
28. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd
29. Experience With an Optical Character Recognition Search Application for Review of Outside Medical Records
30. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease
31. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics
32. Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis
33. Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
34. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
35. Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience
36. Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL
37. Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation: Stem Cell Donation Behaviors
38. Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation
39. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT
40. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing
41. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review
42. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
43. The utility of biomarkers in acute GVHD prognostication
44. Long-Term Pulmonary Function Trajectories After Allogeneic Bone Marrow Transplantation
45. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience
46. Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience
47. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
48. Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma
49. Improved accuracy of acute graft-versus-host disease staging among multiple centers
50. Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.